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Objective: To analyze temporal patterns of antiretroviral (ARV)
prescribing practices relative to nationally defined guidelines in
treatment-naive patients with HIV-1 infection.
Design: Retrospective cohort study.
Methods: We evaluated ARV prescribing patterns among ARV
treatment-naive veterans who were receiving care within the US
Department of Veterans Affairs (VA) from 1992 through 2004 in
comparison to evolving adult HIV-1 treatment guidelines.
Results: A total of 15,934 patients initiated ARV treatment. Since
1999, .94% of patients initiated at least a 3-ARV medication
combination, although the percentage of patients who initiated a
guideline ‘‘preferred’’ or ‘‘alternative’’ regimen never rose to greater
than 72% and was significantly associated with being black and with
region of care. After 1999, 20% of patients started 4 or more active
ARV agents in combination, which was significantly associated with
lower baseline CD4 cell count, higher viral load, and receiving care in
the western United States. The proportion of patients receiving
guideline ‘‘not recommended’’ regimens (virologically undesirable or
overlapping toxicities) was ,1% after 1997. VA prescribing trends
generally predated guideline recommendations by 6 to 12 months.
Conclusions: VA prescribing patterns for ARV initiation adhere
to treatment guidelines that maximize safety. Guidelines designed
to maximize efficacy were not followed as stringently. Evaluating
clinical practice patterns against contemporary treatment guidelines
can inform guideline development.
Key Words: antiretroviral, epidemiology, guidelines, HIV, patient
safety, regional variation, veterans
(J Acquir Immune Defic Syndr 2007;44:20–29)
Evidence-based treatment guidelines are increasingly usedto guide clinicians’ medical care decisions in a variety of
chronic diseases.1 Expert panels, independent or convened by
government agencies, develop and revise evidence-based
guidelines. Evaluations of the quality of health care delivered
and reimbursement decisions by payers are increasingly
related to providers’ adherence to published guidelines.
Rapid development of successful antiretroviral (ARV)
therapies has dramatically changed the treatment of HIV
infection. After 1996, when the use of combination ARV
medications became standard, HIV infection was transformed
from a rapidly progressive and nearly uniformly fatal condition
to a treatable chronic infection.2 The complexity of ARV
treatment has reduced ARV adherence and increased drug–
drug interactions and metabolic toxicities, however. Although
many ARV combinations are widely recognized as standard
treatment, other ARV combinations are discouraged because
of excess toxicities, regimen complexity, or adverse drug
interactions.2 HIVexpert panels have developed guidelines for
initiation and appropriate use of ARVs in HIV-1 infection to
account for this complexity of ARV management.2–5
The influence of the HIV treatment guidelines on
clinical practice and outcomes is potentially important but
understudied. In particular, better understanding of treatment
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patterns contemporary with guidelines might show that evolv-
ing guidelines lead to changes in practice patterns or that
guideline recommendations actually lag behind usage patterns.
Several researchers have described ARV utilization patterns
but have not specifically studied rates of adherence to HIV
treatment guidelines.6–17 We examined the relation between




ARV data were analyzed using the US Department of
Veterans Affairs (VA) immunologic case registry (ICR), which
contains demographic and clinical data from VA clinical
records.18–22 Patients who received at least 1 annual service
contact between January 1992 and December 2004 were
included. ARV treatment-naive patients were defined as
subjects who had not received an ARV prescription from
the VA and whose date of first ARV prescription was at least
1 month after ICR entry. We excluded patients who had an
HIV-1 viral load ,500 copies/mL at any point 3 months
before their first recorded treatment.
Patients were classified by age (based on their age on
January 1 of the relevant year: 18–30, 31–40, 41–50, 51–60,
61–70, and $71 years). Patients were assigned to 1 of 6
predesignated VA race/ethnicity groups: non-Hispanic white,
Hispanic, black, Pacific Islander/Asian, American Indian/Alaskan
native, and other (patients with missing race/ethnicity infor-
mation). Finally, patients were classified into 1 of 4 geographic
regions in the United States (East, South, Midwest, and West)
according to first ICR entry.
Antiretroviral Classifications
ARVmedications were grouped into 3 classes: (1) nucleo-
side reverse transcriptase inhibitor (NRTI), (2) non nucleoside
reverse transcriptase inhibitor (NNRTI), and (3) protease
inhibitor (PI). ARV regimens were defined as (1) monotherapy,
or treatment with a single NRTI, NNRTI, or PI; (2) combination
NRTI therapy, consisting of 2 or more NRTIs used together
with no other class of ARV; and (3) dual-class therapy, consist-
ing of at least 2 NRTIs in conjunction with at least 1 PI or
1 NNRTI. Ritonavir (RTV) prescribed at $400 mg/d was
considered an additional ARV agent.
Statistical Analyses
We compared patterns of ARV use in the VA with
recommendations from published statements of National
Institutes of Health (NIH) consensus conferences (1990 and
1993)23,24 and from the International AIDS Society-USA
(IAS-USA) Panel (1996 and 1997).25,26 In 1998, the VA
formally adopted the US Department of Health and Human
Services (DHHS) guidelines, after which we compared
patterns of ARV use in the VAwith these guidelines. We com-
puted the number of patients initiating ARV regimens
according to categories specified in the guidelines: (1)
‘‘preferred,’’ (2) ‘‘alternative,’’ (3) ‘‘generally not recom-
mended,’’ and (4) ‘‘not recommended.’’ We created a fifth
category, ‘‘other,’’ for regimens that did not fall into 1 of the 4
guideline-specified categories. For not-recommended regi-
mens, we distinguished between those having overlapping
toxicity and those having modest antiviral activity. For ‘‘other’’
regimens, we computed the frequency of different ARV
components as well as the number and proportion of patients
according to the number of agents in the regimen (1, 2, 3, or
$4). We further calculated the number of agents in regimens,
independent of the guideline classification.
Logistic regression was used (variables included age
group, gender, race/ethnicity, US region, clinic size, academic
affiliation, CD4 cell count, HIV-1 viral load within the
3 months preceding initiating therapy, and duration of care
in VA) to determine why patients received a preferred or
alternative regimen compared with ‘‘other’’ regimen as initial
therapy. We carried out similar analyses using 3 versus 4 (or
more) agents in combination as the dependent variable
regardless of guideline status. Univariate and multivariate
odds ratios (ORs) were calculated using the Intercooled
STATA 8.0 for Windows 98/95 NT statistical software
package (Stata Corporation, College Station, TX).
RESULTS
Guideline Development
Table 1 lists US guidelines on ARV treatment for HIV-
1–infected ARV-naive adults. Initial NIH recommendations
in 1990 and 1993 advocated use of zidovudine (ZDV) or
didanosine (ddI) for patients with CD4 counts ,500
cells/mL.23,24 In 1996 and 1997, IAS-USA Panel guidelines
recommended combination NRTI and dual-class therapy,
respectively.25,26 In 1998, the DHHS established a new format
that contained 25 preferred, 10 alternative, and 4 not-
recommended regimens.2
Until February 4, 2002, updates primarily reflected the
availability of newly approved agents; recommendations con-
cerning the isolated use of drugs with limited bioavailability
without RTV; and greater emphasis on regimens with less
toxicity, cross-resistance, or lower pill burden. Combinations
on the preferred list peaked at 36 regimens in May 1999. The
July 4, 2003, update contained several important changes:
(1) reformatting the table displaying the preferred regimens,
(2) reducing the list of preferred regimens to 5, and (3) dis-
tinguishing preferred NNRTI-based regimens from PI-based
regimens. Updates in 2004 included substantially more
alternative regimens.
Reference Cohort
During the study period, 57,210 unique patients were
entered into the ICR. Patients were excluded if they were
missing values for gender, date of first ICR data entry, or age
(N = 397). Further excluded were patients older than 99 years
or younger than 19 years (N = 19) and those whose date of
AIDS diagnosis was recorded as before 1985 or after 2004
(N = 230). The final population included 56,564 living
individuals, of whom 15,934 comprise the treatment-naive
population from 1992 through 2004.
21
J Acquir Immune Defic Syndr  Volume 44, Number 1, January 1, 2007 Guideline Adherence in Prescribing Medications
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. 
Demographics and Clinical Outcomes
The number of unique treatment-naive patients was
1558 in 1992, increasing to a high of 2310 in 1996 and
steadily declining to 651 through December 2004. More
than 97% of patients were men. In 1992, 14% of treatment-
naive patients were 51 years of age or older compared with
31% of patients in 2004. Individuals identified as white
declined progressively from 1992 through 2004, whereas
those identified as black and other increased. Finally, the
number of patients receiving care in the South increased,
whereas the number of patients receiving care in the East
decreased.









1 3/3/1990 ZDV recommended 1 0 0 0
2 12/1/1993 ddI and ddC added as alternative NRTIs if intolerant to ZDV 1 2 0 0
3 7/10/1996 Dual NRTI with PI if available first recommended 4 13 0 0
4 6/25/1997 Dual NRTI + PI preferred recommendation, NNRTI offered as
alternative
15 5 0 0
5 4/24/1998 5 choices of NRTI combinations
5 choices of PIs
25 10 10 2†
6 6/17/1998 SQV-HGC without RTV moved to not recommended 20 10 10 2†
7 12/1/1998 EFV added to preferred regimens 25 10 10
8 5/5/1999 ddI/3TC added to preferred regimens
Triple NRTI (ABC/ZDV/3TC) added as alternative regimen
36 11 10 2†
9 1/28/2000 EFV moved to top of preferred list of NNRTIs or PIs
Reduced preferred NRTIs to 4 combinations
(ddI or 3TC) + (ZDV or d4T)
16 14 10 2†
Alternative NRTI combinations either (ddI + 3TC) or
(ZDV + ddC)
2†
ABC/ZDV/3TC dropped from alternative list, but ABC included
in alternative list with ddI/3TC or ZDV/ddC
Reinforced that SQV-HGC only to be used as with RTV 2†
10 2/5/2001 Added LPV/r and IND/RTV to preferred regimens 24 14 2*
11 4/23/2001 Detailed discussion of RTV used with P (‘‘boosted Pls’’) 24 14 2* 2†
12 8/13/2001 Moved (ddI + 3TC) to preferred list 24 7 2*
13 2/4/2002 No essential changes 30 7 3* 2†
Mentioned limited data on TDF, so generally not recommended
14 7/4/2003 Reformatted table (NNRTI- and PI-based preferred regimens) 5 16 0 2†‡
Fewer preferred regimens
Added TDF as a preferred NRTI
Fewer regimens overall (ddC gone altogether, ddI now only
recommended as alternative with EFV + 3TC)
Preferred NNRTI-based regimens are EFV/3TC combined with
other NRTI (ZDV/TNF/d4T)
Preferred PI-based regimen are LPV/r + 3TC + (ZDV or d4T)
ABC/3TC/ddC dropped from alternative list
ABC/3TC + (ZDV or d4T) added to alternative list
15 11/10/2003 FTC added as an alternative to 3TC in all regimens 5 30 0 2†‡
16 3/23/2004 fosA and fosA/r added as alternative PI-based regimens 5 56 0 2†‡
ABC/3TC added as alternative 2-NRTI backbone
AMP/r and IDV (unboosted) removed as alternative PI-based
regimen
6 87 0 2†‡
17 10/29/2004 d4T moved from preffered list to alternative list
because of increasing reports of d4T-associated toxicities
TDF/3TC (or FTC) recommended as a 2-NRTI backbone for
NNRTI- and PI-based regimens
FTC an option for part of a preferred or alternative 2-NRTI
backbone
ABC, indicates abacavir; d4T, stavudine; EFV, efavirenz; fosA, fosamprenavir; FTC, emtricitabine; IND, indinavir; LPV, lopinavir; TNF, tenofovil; /r, ritonavir-boosted; RTV,
ritonavir; SQV-HGC, saquinavir–hard-gel capsule; 3TC, lamivudine; TDF, tenofovir.
*Addition of hydroxurea with any ARVs.
†Includes 2 general classes of not recommended ARV regimens: toxicity based (ZDV/d4T, ddC/ddI, ddC/3TC, ddC/d4T) and those with modest activity (all monotherapies).
‡In 2003, 2 agent ARV combinations were classified as having modest activity and therefore not recommended.
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Initial Combination Regimens and
Guideline Recommendations
In 1992, 1255 patients (81.2%) initiated ZDV mono-
therapy, the preferred single-agent NRTI regimen at the time,
whereas the remaining 290 patients (18.8%) received ddI or
zalcitabine (ddC) monotherapy or a 2-agent NRTI regimen
(Table 2). The proportion of patients receiving 2-agent
combinations increased from 4.4% in 1992 to 53.6% in 1996.
The use of single-agent NRTI regimens for treatment
initiation decreased to 2.3% of all initial ARV regimens
prescribed in 1997 and has remained at ,2%. The use of
2-agent NRTI combinations peaked in 1996, which is the only
year that guidelines listed this combination as a preferred
regimen. Approximately 80% of 2-agent combinations used
in 1996 were from the preferred list.
Dual-class regimens consisting primarily of 3 or 4
agents were prescribed to 26% of patients in 1996, increasing
to 64% in 1997. By 1999, the proportion receiving 3- or
4-agent combinations exceeded 94%. From 1997 onward, no
more than 72% of patients initiated preferred or alternative
dual-class regimens. Alternative regimens were used at
a consistently lower rate than preferred regimens and were
used in ,1% of patients between 2000 and 2002. From 1998
onward, the use of ‘‘other’’ regimens not on the preferred or
alternative list has ranged from 21% to 56%, with 15% to 24%
of patients receiving 4 (or more) agents as an ‘‘other’’ initial
regimen.
PI-based regimens have been recommended since 1997,
although they were a frequently used alternative option in
1996 (N = 354). The percentage of patients receiving
a preferred PI-based regimen has declined steadily since
1997 and was equivalent to 6.5% in 2004. NNRTI-based
regimens were added to the preferred list in 1999 and have
remained stable at between 29% and 36% since 2000.
Because the categories of not recommended and
generally not recommended regimens were introduced in
1998, the use of these regimens has been consistently low
(see Table 2). Before this, use of regimens that were
subsequently recommended to be virologically undesirable or
had overlapping toxicities varied between 8.3% (1993 and
1994) and 13% (1996). After 1998, no one received any of these
TABLE 2. Trends in Treatment-Naive Regimens According to Guidelines, 1992 Through 2004
Year 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
No. Patients 1558 1275 1354 1608 2310 1743 1180 1002 805 861 781 806 651
Preferred regimens
Single NRTI 1243 882 882 838 97
Dual NRTI 977
Dual-class regimens
PI based 754 691 395 206 215 134 65 42
NNRTI based 212 230 249 202 240 235
Total, % 79.8% 69.2% 65.1% 52.1% 46.3% 43.3% 58.6% 60.6% 54.2% 53.9% 43.0% 37.8% 42.5%
Alternative
Single NRTI 281 266 238 40
Dual NRTI 140
Triple NRTI 13 4 1 0 53 12
Dual-class regimens 354 37 105 93 1 1 0 89 100
Total, % 22.0% 19.6% 14.8% 23.1% 2.1% 8.9% 10.6% 0.6% 0.2% 0.0% 17.6% 17.2%
Generally not recommended 118 41 0 0 0
Total, % 10.0% 4.1% 0.0% 0.0% 0.0%
Not recommended
Toxicity based 0 0 0 0 0 0 0
Modest activity 13 5 1 9 5 20 23
Total, % 1.1% 0.5% 0.1% 1.0% 0.6% 2.5% 3.5%
Other
Single-agent regimen 245 0 61 130 349 40
2-agent combination 68 110 138 350 121 585 17 12 22 22 16
3-agent combination 2 2 7 46 140 130 57 34 169 185 238 115 88
4 (or more)-agent combination 0 0 0 6 97 197 178 197 172 179 186 224 151
Total, % 20.2% 8.8% 15.2% 33.1% 30.6% 54.6% 21.4% 24.3% 45.1% 44.8% 56.3% 42.1% 36.7%
Total single-agent regimen 1488 1163 1209 1206 481 40 13 5 1 9 5 9 10
95.5% 91.2% 89.3% 75.0% 20.8% 2.3% 1.1% 0.5% 0.1% 1.0% 0.6% 1.1% 1.5%
Total 2-agent combinations 68 110 138 350 1238 585 131 51 22 22 16 10 13
4.4% 8.6% 10.2% 21.8% 53.6% 33.6% 11.1% 5.1% 2.7% 2.6% 2.0% 1.2% 2.0%
Total 3-agent combinations 2 2 7 46 494 921 858 750 610 651 574 563 477
0.1% 0.2% 0.5% 2.9% 21.4% 52.8% 72.7% 74.9% 75.8% 75.6% 73.5% 69.9% 73.3%
Total 4-plus agent combinations 0 0 0 6 97 197 178 196 172 179 186 224 151
0.0% 0.0% 0.0% 0.4% 4.2% 11.3% 15.1% 19.6% 21.4% 20.8% 23.8% 27.8% 23.2%
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combinations. The proportion of patients receiving regimens
with modest activity has generally been ,1% to 3%.
Use of 3-Agent ‘‘Other’’ Combinations
Table 3 summarizes the 3-agent ‘‘other’’ combinations
from 1996 through 2004. The number of ‘‘other’’ regimens
increased from 34 in 1999 to 238 in 2002. The decrease in
‘‘other’’ regimens in 2004 reflected, in part, the increase in
alternative regimens, from 7 in 2002 to 87 in 2004.
In 1996 and 1997, triple NRTIs and saquinavir in
combination with 2 NRTIs were the most common 3-agent
‘‘other’’ combinations. Efavirenz was part of the most com-
monly prescribed 3-agent ‘‘other’’ regimen 1 year before being
included in a preferred regimen (1998). Nevirapine in
combination with 2 NRTIs was widely used from 2000
through 2002. A triple-NRTI regimen consisting of abacavir,
lamivudine, and ZDV was listed as an alternative regimen in
1999. From 2000 through 2002, this combination was omitted
from the alternative list, becoming one of the most commonly
prescribed 3-agent ‘‘other’’ regimens. In 1999, abacavir and
tenofovir use began, steadily representing a greater proportion
of ‘‘other’’ regimens from 2000 onward.
Factors Associated With Use of Preferred
and/or Alternative Combinations Compared
With ‘‘Other’’ Combinations
Table 4 shows the odds of using preferred or alternative
combinations, compared with ‘‘other’’ combinations from
1996 through 2004. In univariate analyses, patients were
significantly more likely to receive a preferred or alternative
regimen if they were 61 to 70 years of age, were black,
received care other than in the western US, had CD4 counts
between 201 and 350 cells/mL (or data not recorded or not
available), had an HIV-1 viral load between 20 and 50,000
copies/mL (or missing), or started treatment before 1999
(except for 1997). Adjustment for all factors simultaneously in
multivariate logistic regression analysis revealed that factors
associated with greater odds of receiving a preferred or
alternative regimen still included being 61 to 70 years of age,
being black, receiving care other than in the western US,
having CD4 counts between 201 and 350 cells/mL (or data not
recorded or not available), having an HIV-1 viral load between
20 and 50,000 copies/mL (or missing), or starting treatment
before 1999 (except for 1997). A greater odds of receiving
‘‘other’’ regimens included clinic size .50 patients and
receiving care in the western US.
Factors Associated With Use of 3-Agent Versus
4 (or more)-Agent Combinations
Age, gender, clinic size, and academic affiliation were
not associated with greater use of 3-agent regimens (see Table
4). The odds of receiving 3 versus 4 or more agents were
significantly greater in blacks, those starting treatment before
1999, and those with .7 months of follow-up preceding
treatment. The odds of receiving 4 or more agents were higher
in thewestern US, in thosewith CD4 counts,200 cells/mL, and
in those with viral loads .50,000 copies/mL (univariate only).
Treatment Initiation Patterns Relative to
Guideline Updates
Figure 1 displays the frequency of ARV regimen initiation
relative to the timing of guideline recommendation announce-
ments. In almost all cases, clinical practice patterns anticipated
guideline recommendations by 6 to 12 months, particularly for
regimens that were initially listed as preferred or alternative and
later listed as alternative or not recommended (ie, mono-
therapies, unboosted PIs). Despite being listed as not generally
recommended (for too little data available), tenofovir use
increased significantly 15 months before being listed on the
preferred list. For ARVs that were only listed as preferred,
clinical utilization anticipated the guidelines for lopinavir and
was simultaneously adopted for efavirenz-containing regimens.
DISCUSSION
Professional group–derived treatment guidelines have
been important vehicles for communication of scientific
advancements, limitations, risks, and proper use of new
therapies. Our study is the first comparing ARV utilization
patterns with contemporary guideline recommendations in
HIV-infected treatment-naive patients. That insurance was
not a barrier for ARV access was of particular importance.
TABLE 3. Distribution of 3-Agent ‘‘Other’’ Combinations
1996 1997 1998 1999 2000 2001 2002 2003 2004
Total other 3-drug regimens 140 130 57 34 169 185 238 115 88
Triple NRTIs* 116 34 5 1 32 81 116 15 7
Total, % 82.0% 26.2% 8.8% 2.9% 18.9% 43.8% 48.7% 13.0% 8.0%
NNRTI + 2 NRTIs* 3 4 28 102 63 53 4 3
Total, % 2.1% 3.1% 49.1% 60.4% 34.1% 22.3% 3.5% 3.4%
PI + 2 NRTIs* 20 82 4 2 13 7 1 12 13
Total, % 14.3% 63.1% 7.0% 5.9% 7.7% 3.8% 0.4% 10.4% 14.8%
Dual-PI or PI + NNRTI* 1 10 20 13 11 10 4 9 4
Total, % 0.7% 7.7% 35.1% 38.2% 6.5% 5.4% 1.7% 7.8% 4.5%
ABC- or TDF-containing 18 11 24 64 75 61
Total, % 52.9% 6.5% 13.0% 26.9% 65.2% 69.3%
*NRTIs do not include TDF or ABC.
ABC indicates abacavir; TDF, tenofovir.
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Variable Univariate Multivariate Univariate Multivariate
Age (y)
18–30 554/974 57% Ref 531/647 82% Ref
31–40 2002/3401 59% 1.05 1.03 1871/2258 83% 1.02 1.04
41–50 2271/3850 59% 1.04 1.01 2249/2694 83% 1.05 1.16
51–60 840/1409 60% 1.02 1.04 921/1109 83% 1.03 1.28
61–70 260/414 63% 1.37* 1.36* 259/308 84% 1.12 1.41
71+ 55/91 60% 1.09 1.16 65/76 86% 1.25 1.65
Gender
Male 5843/9914 59% Ref 5751/6923 83% Ref
Female 139/225 62% 1.18 1.20 145/169 86% 1.22 1.23
Race
White 1712/3001 57% Ref 1703/2127 80% Ref
Black 3269/5416 60% 1.13* 1.14* 3177/3741 85% 1.28† 1.32‡
Other 1001/1722 58% 1.04 1.09 1016/1224 83% 1.16 1.31*
US Region
East 1874/3072 61% Ref 1810/2120 85% Ref
South 2286/3780 60% 1.12 0.84 2315/2747 84% 0.92 1.02
Midwest 622/1040 60% 1.04 0.96 533/627 85% 0.97 0.98
West 1200/2247 53% 0.80† 0.66‡ 1238/1598 77% 0.59† 0.68‡
CD4 count, cells/mL
501+ 602/1046 58% Ref 608/703 86% Ref
351–500 801/318 61% 1.13 1.17 741/879 84% 0.85 0.86
201–350 1144/1871 61% 1.22* 1.28* 1117/1334 84% 0.82 0.83
101–200 748/1210 62% 1.12 1.21 747/905 83% 0.74* 0.74*
51–100 403/681 59% 1.13 1.2 413/508 81% 0.68* 0.68*
,51 607/985 62% 1.13 1.08 594/730 81% 0.67* 0.67‡
Missing 1696/3054 56% 0.95 1.57† 1694/2053 83% 0.74* 0.75
HIV-1 RNA viral load, copies/mL
500–20,000 1034/1841 62% Ref 1121/1337 86% Ref
20,001–50,000 672/1078 60% 1.21* 1.21* 742/861 81% 1.17 1.25
50,001–100,000 518/860 61% 1.16 1.17 587/729 80% 0.77* 0.85
100,001+ 971/1600 58% 1.12 1.13 1071/1331 83% 0.76† 0.88
Missing 2522/4347 58% 0.99 0.82* 2074/2487 84% 0.94 1.06
CD4 percent
0–6 713/1155 62% Ref 713/878 81% Ref
7–15 1154/1883 61% 0.98 0.93 1139/1395 82% 1.00 0.91
16–21 744/1236 60% 0.93 0.91 733/876 84% 1.16 0.91
22+ 1257/2086 60% 0.95 1.04 1230/1438 86% 1.36† 1.07
Missing 1922/3443 56% 0.77*** 0.62‡ 1869/2252 83% 1.10 1.07
CD8 count, cells/mL
,436 623/1028 61% Ref 615/726 85% Ref
436–701 804/1325 61% 0.95 0.97 809/964 84% 0.96 0.87
702–1086 898/1562 57% 0.88 0.92 899/1099 82% 0.83 0.73*
1087+ 956/1572 61% 1.06 1.15 932/1113 84% 0.95 0.84
Missing 2705/4657 58% 0.91 1.17 2645/3195 83% 0.86 0.77
Year of first ARV regimen
2004 389/651 60% Ref 477/595 80% Ref
2003 447/806 55% 0.94 0.92 562/732 77% 0.83 0.85
2002 336/781 43% 0.48‡ 0.48‡ 574/712 81% 1.04 1.07
2001 466/861 54% 0.83 0.83 651/783 83% 1.21 1.25
(continued on next page)
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Therefore, we could explore other factors that may influence
ARV prescribing patterns.
The correlation between prescribing patterns and
guidelines was greatest for recommendations that inform
physicians what not to do so as to avoid harm rather for than
recommendations that inform physicians what to do so as to
improve efficacy. This difference could reflect a number
of factors, including a large and rapidly changing number,
complexity and scope of recommendations, lag in available
new evidence and publication of guidelines, varying in-
terpretation of evidence between guideline committees and tre-
ating physicians, and local and regional considerations (eg,
patient mix) that may affect treatment patterns.
We found systematic differences in ARV treatment
among blacks compared with nonblacks. A number of
previous studies reveal disparities in HIV care related to
race.11–13,15,16,27 Factors associated with non-HAART regimens
in non-VA settings include active substance abuse,7,28
inconsistent clinical follow-up,9 and lack of insurance.11,15
In the VA, blacks compared with nonblacks were more likely
to receive preferred or alternative regimens and less likely to
receive 4 (or more)-agent regimens, however. We know of no
data (even in the guidelines) suggesting that blacks respond
more or less effectively than nonblacks to 3-agent regimens.
We also cannot ascertain the extent to which the choice was
based on the regimen’s convenience, tolerability, provider
perceptions, or patient preferences. Recent provider survey
data indicate that ARV treatment decision-making may be
influenced by race or underlying HIV risk factors.29 In
addition, patient involvement in the treatment decision-making
process is likely to influence initial choices as well.30,31
Patients receiving care in the western US were more
likely to be prescribed ‘‘other’’ regimens and more than 3
agents in combination. Regional variation in clinical care has
been a subject of intense study for decades.32 Significant
regional variation in clinical practice has been described
for a variety of chronic diseases but has not been previously
described in any detail for ARVuse.33 No consistent explanation
can account for this phenomenon observed in the management
of chronic non-HIV diseases. Although patient preferences and
economic incentives (ie, payer mix, reimbursement rates, access
to or limitations in care) may account for some of the variation,
economic incentives are not an issue in the VA. Yet, the VA
is subject to the same regional variation in chronic disease
practice patterns even after accounting for risk adjustment.34
Further analysis indicates that VA clinical practice mirrors local
community practice and may simply reflect local provider
opinions and patient preferences. Variation in ARV use is
unlikely explained by differences in VA HIV provider
experience or VA infrastructure differences compared with
local community practice. Seventy-five percent of VA medical
centers provide HIV care in subspecialty clinics, and the
average VA HIV provider has more than 10 years of HIV
clinical experience, having treated an average of 120 patients in
the last 5 years.35 Our findings highlight the need to understand
the causes and implications of such variation better for the










Variable Univariate Multivariate Univariate Multivariate
2000 441/805 55% 0.85 0.87 610/734 83% 1.20 1.21
1999 713/1002 71% 1.56‡ 1.61‡ 749/895 84% 1.25 1.24
1998 796/1180 67% 1.37* 1.46‡ 858/989 87% 1.60† 1.61†
1997 791/1743 45% 0.57‡ 0.62‡ 921/1073 86% 1.51† 1.50†
1996 1603/2310 69% 1.47‡ 1.87‡ 494/579 85% 1.48* 1.51*
Months of follow-up in ICR preceding first ARV regimen
,2 1376/2274 61% Ref 1497/1834 81% Ref
2–6 1291/2138 60% 0.97 0.98 1317/1626 86% 0.94 0.93
7–12 524/876 60% 0.97 0.97 483/563 86% 1.36* 1.34*
13–24 641/1098 58% 0.89 0.87 576/669 84% 1.38* 1.36*
25–36 453/785 58% 0.88 0.82* 364/432 82% 1.20 1.11
37–60 817/1365 60% 0.95 0.87 611/721 85% 1.22 1.14
61–84 495/900 55% 0.85 0.92 538/628 86% 1.33* 1.21
85+ 385/703 55% 0.73† 0.82 510/619 82% 1.03 1.16
No. patients at treatment facility
,10 19/24 79% Ref 17/18 94% Ref
10–50 158/255 62% 0.42 0.39 162/183 89% 0.47 0.38
51–200 1033/1730 60% 0.39 0.33* 1013/1196 85% 0.32 0.25
.200 4460/7660 58% 0.36* 0.29* 4442/5397 82% 0.27 0.20
Missing 312/470 66% 0.47 0.39 262/298 88% 0.42 0.26
HIV staff on affiliated university faculty 4645/7903 59% 0.88* 0.98 4567/5501 83% 0.93 1.00
*P , 0.05; †P , 0.01; ‡P , 0.001.
Ref indicates reference.
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health of persons with HIV as well as the need to initiate
targeted approaches to reduce unwarranted variation.
Whether patients may have received ARV prescriptions
from outside the VA that were not recorded in the ICR is
important to our study’s validity. A recent representative
survey of 573 veterans found that ARVs were obtained by
veterans (primarily treatment experienced) outside the VA at
a rate of,3.8%.36 More than 80% of patients had greater than
FIGURE 1. Initiation of ARV ther-
apy relative to guideline develop-
ment. Designated areas indicate
guideline recommendation peri-
ods for the specific recommenda-
tion. A indicates alternative; N, not
recommended; P, preferred; Q,
generally not recommended. Line
indicates number of prescriptions
written during each quarter of the
calendar year represented. Y-axis
indicates percentage of patients
receiving the ARV regimen. EFV
indicates efavirenz; IDV, indinavir;
NVP, nevirapine; unboosted, PI
treatment without low-dose RTV;
3TC, lamivudine.
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2 months of follow-up in the ICR before ARV initiation.
Extending follow-up to 3 months before treatment initiation
did not change our findings (data not shown). Recent data from
Gandhi and colleagues37 indicate that 40% of HIV-positive
veterans received care in the VA for an average of 3 years
before their HIV diagnosis and entry into the ICR, empha-
sizing that a significant minority of veterans are already in care
for years before diagnosis; therefore, ARV treatment initiation
outside the VA would be unlikely. We cannot completely
exclude the possibility that patients had prior ARV use and
appeared in the ICR as ARV treatment naive. It is possible
then, but unlikely, that ARV initiation choices in VA could
have been affected or biased by ARV treatment history not
recorded in the ICR.
A substantial number of the patients started treatment
well below the CD4 cell count thresholds that were suggested by
contemporary guidelines. Of those veterans initiating treatment
between 1998 and 2000, when the guidelines suggested that
treatment should be initiated when the CD4 count was ,500
cells/mL, on average, 60% had a CD4 count,350 cells/mL and
40% had a CD4 count ,200 cells/mL when treatment was
initiated. Between 2001 and 2004, when the guidelines
suggested that treatment should be initiated when the CD4
count was,200 cells/mL and should be offered when the CD4
count was ,350 cells/mL, on average, 25% had a CD4 count
,100 cells/mL and 15% had a CD4 count of ,50 cells/mL at
the time of treatment initiation. Our findings support evidence
that this is a consequence of delayed identification of HIV
infection rather than lack of adherence to treatment guidelines.
A recent VA study found that 55% of patients whowere recently
diagnosed with HIV infection had CD4 counts ,200
cells/mL.37 This may correlate with key organizational, patient,
or practitioner factors currently not recorded in the ICR such as
hard-to-reach populations living in settings far from a VA
facility13 or comorbidities such as homelessness, mental illness,
or substance abuse. As reported elsewhere, our data may help to
identify strategies to narrow gaps related to disparities in care
access, treatment, and outcome.38,39
The relatively high rate of ‘‘other’’ regimens suggests that
research is warranted to assess how being assigned to different
categories of ARV use—preferred, alternative, and 3- to 4-drug
‘‘other’’ combinations—is related to clinical outcomes. Some of
the use of ‘‘other’’ combinations may be explained by revisions
in guideline statements and preferred use of other agents, notably
nevirapine, abacavir, and tenofovir. A recent study addressing
this question in children initiating ARV treatment found that
22% were not placed on guideline-recommended regimens and
that 15% were started on ‘‘other’’ ARV combinations.40
After 1997, approximately 20% of initial ARV regimens
contained 4 or more active agents and were more likely to be
prescribed to patients with lower CD4 cell counts and higher
viral loads. This suggests that practitioners were augmenting
regimens with additional agents in patients who were at
particularly high risk for HIV complications or that patients
were deemed less likely to respond to a recommended 3-agent
regimen. Reports from at least 1 other large cohort indicate
that a small percentage of patients (5%) were started on ARV
regimens of 4 or more agents, although the reasons for such
decisions were not given.41 Several small studies comparing
treatment initiation with 3 versus 4 or more ARV drugs in
ARV-naive patients suggest equivalent virologic outcomes.
Nevertheless, there is a suggestion that more ARV drugs may
accelerate the timing and percentage of those achieving an
undetectable viral load.42–44
Our study suggests that providers anticipated many
guideline recommendations well before their publication. This
may be explained, in part, by the lengthy process required for
expert panel review or the fact that firm recommendations
cannot be made until there are adequate data on potential
efficacy or toxicities of specific regimens. Some guideline panel
recommendations and updates are published in peer-reviewed
journals, further lengthening the time to publication and
availability to providers. The DHHS guidelines were originally
published in 1998, however, with 1 update appearing in a peer
review publication in 2002.45,46 DHHS updates have consis-
tently been updated electronically and are therefore available to
VA practitioners via the Internet when released. As guidelines
became released more often than annually and by the DHHS,
the time between mean uptake/decrease and official guideline
recommendations has narrowed.
Our study also suggests that adherence to safety
recommendation guidelines is closely followed and serves
as an important benchmark. Conversely, lower practitioner use
of ARV effectiveness guidelines (possibly because of the
rapidly changing nature and complexity of suggestions)
suggests that simplification of guidelines should be studied
to increase potential adherence.
There are numerous examples of departure from
clinical practice guidelines,47 including examples in HIV
primary care. For example, current US Public Health Service
(USPHS) guidelines recommend tuberculin skin testing
(TST) for all newly diagnosed HIV-infected patients. A
recent study in US clinics found that just more than half of
the newly diagnosed patients had received TST. Patient
demographics had little effect on adherence to guidelines.
Factors associated with higher TST guideline adherence
included underlying risk factors for tuberculosis, increased
clinic visits, use of other prophylactic medications for HIV
care, and a written policy for TST in the clinic.48 Whether
HIV treatment decisions based on adherence or nonadher-
ence to guideline recommendations result in significant
clinical outcome differences requires study. Improved under-
standing of the relation of providers’ prescribing behavior to
ARV treatment guidelines may help to identify ways to
improve development and timely communication of future
treatment guidelines.
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